Indivior PLC (INDV)
USD 11.98
(3.72%)
USD 11.98
(3.72%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4 Million USD | 28.76% |
| 2022 | 205.2 Million USD | 11.64% |
| 2021 | 183.8 Million USD | 95.94% |
| 2020 | 93.8 Million USD | -55.28% |
| 2019 | 209.76 Million USD | -33.85% |
| 2018 | 317.1 Million USD | -25.09% |
| 2017 | 423.31 Million USD | 25.27% |
| 2016 | 337.91 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 35.07 Million USD | -47.42% |
| 2024 Q3 | 4 Million USD | -88.59% |
| 2024 Q1 | 66.7 Million USD | 8.34% |
| 2023 Q2 | 69.96 Million USD | -1.53% |
| 2023 FY | 264.21 Million USD | 28.76% |
| 2023 Q4 | 61.56 Million USD | 134.91% |
| 2023 Q1 | 71.05 Million USD | 127.02% |
| 2023 Q3 | -176.38 Million USD | -352.11% |
| 2022 FY | 205.2 Million USD | 11.64% |
| 2022 Q4 | -262.92 Million USD | -569.45% |
| 2022 Q3 | 56 Million USD | -6.9% |
| 2022 Q2 | 60.15 Million USD | 15.9% |
| 2022 Q1 | 51.9 Million USD | 61.71% |
| 2021 FY | 183.8 Million USD | 95.94% |
| 2021 Q4 | 32.09 Million USD | 0.0% |
| 2020 FY | 93.8 Million USD | -55.28% |
| 2019 FY | 209.76 Million USD | -33.85% |
| 2018 FY | 317.1 Million USD | -25.09% |
| 2017 FY | 423.31 Million USD | 25.27% |
| 2016 FY | 337.91 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 97.429% |
| Theratechnologies Inc. | -10.62 Million USD | 62.36% |
| Safety Shot Inc | -12.18 Million USD | 67.17% |
| Cosmos Health Inc. | -21.83 Million USD | 81.678% |
| Cronos Group Inc. | -81.37 Million USD | 95.085% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 101.914% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 89.784% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 131.936% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -13.418% |
| ProPhase Labs, Inc. | -21.61 Million USD | 81.493% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 14.912% |
| Dynavax Technologies Corporation | -37.02 Million USD | 89.197% |
| Radius Health, Inc. | -3.92 Million USD | -1.911% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -59.032% |
| Alvotech | -354.86 Million USD | 98.873% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 16.411% |
| Alpha Teknova, Inc. | -35.56 Million USD | 88.752% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 97.49% |
| SCYNEXIS, Inc. | 72.66 Million USD | 105.504% |
| Harrow Health, Inc. | 580 Thousand USD | 789.655% |
| Biofrontera Inc. | -22.67 Million USD | 82.361% |
| DURECT Corporation | -36.88 Million USD | 89.155% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 24.084% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 108.516% |
| OptiNose, Inc. | -22.74 Million USD | 82.416% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 131.666% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 73.513% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 35.596% |
| SIGA Technologies, Inc. | 83.62 Million USD | 104.783% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 142.868% |
| Shineco, Inc. | -17.06 Million USD | 76.561% |
| Phibro Animal Health Corporation | 53.31 Million USD | 107.503% |
| Procaps Group S.A. | 52.32 Million USD | 107.645% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 53.068% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 15.553% |
| Viatris Inc. | 766.2 Million USD | 100.522% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 16.411% |
| Rockwell Medical, Inc. | -6.67 Million USD | 40.03% |
| Incannex Healthcare Limited | -30.04 Million USD | 86.685% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 23.868% |
| Tilray Brands, Inc. | -174.74 Million USD | 97.711% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 102.396% |
| PetIQ, Inc. | 60.01 Million USD | 106.665% |
| Silver Spike Investment Corp. | 7.34 Million USD | 154.495% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 101.594% |
| Journey Medical Corporation | -2.07 Million USD | -92.957% |
| Alimera Sciences, Inc. | -1.47 Million USD | -171.924% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 70.626% |
| Assertio Holdings, Inc. | -243.53 Million USD | 98.358% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 32.116% |
| Embecta Corp. | 221.5 Million USD | 101.806% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 80.05% |
| Procaps Group, S.A. | 38.97 Million USD | 110.264% |
| PainReform Ltd. | -9.58 Million USD | 58.264% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 97.098% |
| Hempacco Co., Inc. | -8.81 Million USD | 54.609% |
| Talphera, Inc. | -16.88 Million USD | 76.316% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 104.562% |
| Alvotech | -354.86 Million USD | 98.873% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 101.097% |
| Kamada Ltd. | 10.06 Million USD | 139.746% |
| Currenc Group, Inc. | -6.64 Million USD | 39.811% |
| Evoke Pharma, Inc. | -7.43 Million USD | 46.171% |
| Flora Growth Corp. | -50.35 Million USD | 92.056% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 80.05% |
| Evolus, Inc. | -49.23 Million USD | 91.875% |
| HUTCHMED (China) Limited | 18.37 Million USD | 121.769% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 102.031% |
| Akanda Corp. | -10.05 Million USD | 60.204% |